Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent Glioblastoma

The purpose of this study is to compare the usual treatment to using the study drugs, relatlimab and nivolumab in patients with recurrent brain cancer. The use of the study drugs, relatlimab and nivolumab, could shrink or stabilize your cancer. But, they could also cause side effects, which the study team will be monitoring. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study drugs increase the life of patients compared to the usual approach.

Are you Eligible? (Inclusion Criteria)

• Are you 18 years of age or older? Has your glioblastoma recurred following treatment with radiation therapy and temozolomide? Are you willing to make regularly scheduled visits to the clinic for treatment and assessment?